Studies find blood marker that may detect CTE in the living

RUKUS· · 2d ← 5d
Go Rogue

Two studies in JAMA report that a tau protein fragment in blood may mark chronic traumatic encephalopathy, a brain disease tied to repeated head blows.

CTE has until now been diagnosable only by brain autopsy after death, so a test for the living would end uncertainty for patients and families.

The Boston University and Banner Health study tested blood given while alive by 21 former football players, 18 later confirmed to have had CTE.

A Washington University School of Medicine study of 11 cases identified the same biomarker, stumbled on during Alzheimer's research.

The test showed promise only for advanced CTE, which brings symptoms like memory loss and severe mood swings, not the symptom-free early stages.

Researchers caution the studies were small and the marker needs validation, but hope a commercial blood test could arrive within five years.

  1. Researchers reported that a new blood test may detect CTE in the living after identifying a marker protein in blood samples from former football players.

    Michael Alosco, co-director of clinical research at Boston University's CTE Center, said in a statement, "We are still in the discovery phase and it's a small sample size," adding that if future studies validate the findings, the test will detect CTE "with a high level of accuracy" and "open the doors to clinical trials and treatment."

  2. In that study, eMTBR-tau levels were significantly higher in high-stage CTE than in low-stage or no CTE, while p-tau217 tracked Alzheimer's pathology rather than CTE.

    The study's authors concluded that plasma eMTBR-tau may represent a feasible biomarker for high-stage CTE and called for larger validation studies to establish its diagnostic accuracy.

    The study's authors forecast that a validated biomarker could transform clinical care by enabling diagnosis during life and accelerating trials and therapeutic development.

  3. The study authors hope the findings lead to a commercially available blood test within five years.

    Washington University researchers found the eMTBR-tau243 marker by chance while testing more than 200 samples, one from a patient without Alzheimer's whose autopsy showed advanced CTE.

    Dr. Chihiro Sato said the biomarker would not stand alone, but a person with repeated head injuries, a negative Alzheimer's test, and the marker might have CTE.

    Dr. Julian Bailes, a brain injury specialist not involved in either study, said they have significant limitations and questions remain, including how to distinguish CTE from Alzheimer's, but he applauded the researchers.

    Dr. Julian Bailes said the blood biomarker could become important for identifying people with high-stage CTE.

    Marc Weisskopf, director of epidemiological studies at the Football Players Health Study at Harvard, commended the study but cautioned against excessive optimism, saying the biomarker is at best a research tool for now.

    Dr. Gil Rabinovici said the results are still preliminary but he could not be more excited about further validating them and bringing hope to people concerned about the illness.

    Dr. Gil Rabinovici said developing a diagnostic test for CTE is an essential first step for drawing the interest of drug developers.

    Dr. Chihiro Sato said the discovery was a matter of serendipity and, though more work needs to be done, it was nonetheless promising.

    Dr. Nicholas Ashton compared identifying the protein in blood to finding one piece of a sugar cube thrown into an Olympic-sized swimming pool within 15 minutes.

  4. A Boston University and Banner Health study published in JAMA on November 19 found elevated eMTBR-tau in blood from 21 former football players, 18 with autopsy-confirmed CTE.

    The five participants who had both CTE and Alzheimer's disease showed the highest eMTBR-tau levels in the study.

    A separate Washington University School of Medicine study based on 11 cases, published in JAMA on November 13, 2026, identified the same blood biomarker.

    Michael Alosco called the blood test a "game changer" in the ability to diagnose CTE in the living.

    Michael Alosco said, "I'm cautiously optimistic that we can really understand this finding and move it forward in the next five years or so."

    Players interviewed split over the prospect of testing: Marcus Mariota said he would take such a test, while Joshua Metellus said he would not want to know while still playing.

  5. Washington University researchers told a dementia meeting in Japan that the eMTBR-tau243 biomarker could not reliably identify early-stage CTE.

    The Washington University team tested stored blood from 11 people with CTE and found higher eMTBR-tau243 levels in those with more advanced disease.

Sign in with subscription

Free during the beta.

Clear all notifications?

Your bells stay on. Only this list empties.